Macrogenics (MGNX) Total Liabilities (2012 - 2026)
Macrogenics (MGNX) posted quarterly Total Liabilities of $196.7 million for Q1 2026, up 35.22% year-over-year from $145.4 million in Q1 2025, and down 2.28% quarter-over-quarter from $201.3 million in Q4 2025.
Macrogenics (MGNX) Total Liabilities (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Total Liabilities for 15 consecutive years, with $196.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 35.22% year-over-year to $196.7 million; the TTM figure through Mar 2026 stood at $196.7 million (up 35.22% YoY), while the FY2025 annual figure was $201.3 million, up 38.23% from the prior year.
- Total Liabilities eased to $196.7 million in Q1 2026 per MGNX's latest filing, from $201.3 million in the prior quarter.
- Across five years, Total Liabilities topped out at $234.2 million in Q1 2023 and bottomed at $72.4 million in Q3 2022.
- Historically, Total Liabilities has averaged $150.7 million across 5 years, with a median of $145.4 million in 2025.
- Annual changes were most pronounced in 2023 — Total Liabilities surged 151.24% — and 2024, when it sank 39.32%.
- Macrogenics' Total Liabilities stood at $138.5 million in 2022, then rose by 5.31% to $145.8 million in 2023, then declined by 0.14% to $145.6 million in 2024, then soared by 38.23% to $201.3 million in 2025, then fell by 2.28% to $196.7 million in 2026.
- Business Quant data shows MGNX's Total Liabilities at $196.7 million in Q1 2026, $201.3 million in Q4 2025, and $203.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | 196.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 196.68 Mn |
| Dec 31, 2025 | 201.26 Mn |
| Sep 30, 2025 | 203.76 Mn |
| Jun 30, 2025 | 198.80 Mn |
| Mar 31, 2025 | 145.45 Mn |
| Dec 31, 2024 | 145.60 Mn |
| Sep 30, 2024 | 144.43 Mn |
| Jun 30, 2024 | 143.32 Mn |
| Mar 31, 2024 | 142.13 Mn |
| Dec 31, 2023 | 145.81 Mn |
| Sep 30, 2023 | 145.99 Mn |
| Jun 30, 2023 | 134.11 Mn |
| Mar 31, 2023 | 234.23 Mn |
| Dec 31, 2022 | 138.46 Mn |
| Sep 30, 2022 | 72.39 Mn |
| Jun 30, 2022 | 75.56 Mn |
| Mar 31, 2022 | 93.23 Mn |
| Dec 31, 2021 | 95.63 Mn |
| Sep 30, 2021 | 100.72 Mn |
| Jun 30, 2021 | 106.87 Mn |